Clinical trials: Depression Diagnosis
Major Depressive Disorder
ALTO-300 in Depression (ALTO-300-004)
The purpose of this study is to collect biologically-based data for defining predictors and correlates of the effects of ALTO-300.
- Trial name
- NCT05157945
- Testing
- ALTO-300 PO Tablet
- Where
- 4 sites in United States
- Volunteers
- 148 people
- Sponsor
- Alto Neuroscience
Major Depressive Disorder
Assess the Efficacy and Safety of ASC-01 in Patients With Major Depressive Disorder
To evaluate the efficacy and the safety of ASC-01 (aripiprazole/sertraline combination) compared to sertraline monotherapy in patients with major depressive disorders who have responded incompletely to sertraline monotherapy.
- Trial name
- NCT02046564
- Testing
- ASC-01
- Where
- 29 sites in Australia, Japan and 3 more
- Volunteers
- 412 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Major Depressive Disorder
The Safety and Efficacy of Brexpiprazole as Adjunctive Therapy in the Treatment of Major Depressive Disorder
This study is a multicenter, randomized, double-blind, placebo-controlled trial designed to assess the efficacy and safety of brexpiprazole as adjunctive therapy in the treatment of Major Depressive Disorder.
- Trial name
- NCT03487198
- Testing
- Brexpiprazole
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Otsuka Beijing Research Institute
Depressive Disorder
A Study of Duloxetine (LY248686) in Japanese Children and Adolescents With Depressive Disorder
The purpose of this study is to determine the efficacy of duloxetine hydrochloride versus placebo in the treatment of Japanese children and adolescents with depressive disorder.
- Trial name
- NCT03315793
- Testing
- Duloxetine Hydrochloride
- Where
- Japan
- Volunteers
- 149 people
- Sponsor
- Shionogi
Major Depressive Disorder
Study Evaluating DVS-233 in Adult Outpatients With Major Depressive Disorder
Primary: To compare the antidepressant efficacy and safety of subjects receiving DVS-233 SR versus subjects receiving placebo. Secondary: To assess the response of subjects receiving DVS-233 SR for the clinical global evaluation…
- Trial name
- NCT00063206
- Testing
- DVS-233 SR
- Volunteers
- 247 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Alopecia Areata, Depressive Episode
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and…
- Conditions
- Alopecia Areata, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04239521
- Testing
- Exposure of interest (studies 2 & 3).
- Where
- United Kingdom
- Volunteers
- 51,955 people
- Sponsor
- Momentum Data
Depressive Disorder, Major
Study to Evaluate the Performance Validity and Test-Retest Reliability of a Computer-Administered Cognitive Test Battery in Participants With Major Depressive Disorder (MDD)
The purpose of this study is to examine concurrent validity of 8 computerized tests intended for the assessment of cognitive function in participants with Major Depressive Disorder (MDD), relative to 8 corresponding and…
- Trial name
- NCT03014544
- Testing
- Computer- administered test battery, Examiner- administered test battery
- Where
- 20 sites in United States
- Volunteers
- 585 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
Tolerability and Pharmacokinetics of Hypidone Hydrochloride in Healthy Subjects
This study will investigate the tolerability and pharmacokinetics of Hypidone Hydrochloride by multiple doses in 36 healthy male and female subjects who are of 18 to 55 years old.
- Trial name
- NCT04598607
- Testing
- Hypidone Hydrochloride tablets
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Zhejiang Huahai Pharmaceutical Co., Ltd.
Major Depressive Disorder
Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD)
The study will assess safety and tolerability of 0.5 mg/day and 1 mg/day of sublingual (under the tongue) formulation of agomelatine (AGO178) in patients with Major Depressive Disorder over a 52-week open-label phase.
- Trial name
- NCT01156415
- Testing
- AGO178
- Where
- 98 sites in United States, Puerto Rico
- Volunteers
- 837 people
- Sponsor
- Novartis Pharmaceuticals
Major Depressive Disorder
A Longitudinal Observational Cohort Study of NSI-189, With Out-Patients With Major Depressive Disorder
All subjects completing the randomized treatment period in Protocol NS2014-1 will discontinue study drug and be asked to provide consent to be followed in this 6-month study, at their final safety visit.
- Trial name
- NCT02724735
- Testing
- NSI-189
- Where
- 12 sites in United States
- Volunteers
- 220 people
- Sponsor
- Neuralstem Inc.
Long Covid, Depression
Development of an Accessible Cognitive Behavioral Therapy Digital Therapeutic for Individuals With Long COVID
This study will evaluate Toivoa-004 as an experimental digital therapeutic for persons with Long COVID suffering from anxiety or depression.
- Conditions
- Long Covid, Depression, Anxiety
- Trial name
- NCT07714889
- Testing
- Rauha® Digital Therapeutic Platform (Toivoa-004)
- Sponsor
- Toivoa Inc
Treatment-resistant Depression
A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
The purpose of this study is to compare the efficacy and safety of switching treatment-resistant depression (TRD) subjects from a prior antidepressant treatment (to which they have not responded) to either intranasal esketamine…
- Trial name
- TRANSFORM-2 (NCT02418585)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant)
- Where
- 48 sites in United States, Czechia and 3 more
- Volunteers
- 236 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms
The purpose of this study is to evaluate the efficacy and overall safety and tolerability of treatment with adjunctive JNJ-40411813 compared to placebo in patients with MDD with anxiety symptoms being treated with an…
- Trial name
- NCT01582815
- Testing
- JNJ-40411813
- Where
- 26 sites in Bulgaria, Hungary and 4 more
- Volunteers
- 121 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
This is a randomized, double blind, placebo controlled, multi-center study to evaluate the effects of NMRA-335140 (formerly BTRX 335140) on symptoms of depression in participants with Major Depressive Disorder (MDD).
- Trial name
- NCT06029426
- Testing
- NMRA-335140
- Where
- 64 sites in United States
- Volunteers
- 383 people
- Sponsor
- Neumora Therapeutics, Inc.
Major Depressive Disorder, Irritability
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
To explore the anti-impulsive and anti-aggressive properties of brexpiprazole in a naturalistic setting of depressed patients with irritability.
- Trial name
- NCT01942785
- Testing
- Brexpiprazole
- Where
- 15 sites in United States
- Volunteers
- 55 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
A Study Comparing the Efficacy and Safety of Duloxetine and Placebo for the Treatment of Depression in Elderly Patients
The purpose of this study is to compare the efficacy and safety of duloxetine 60 mg once daily to placebo on depression in elderly patients (greater than or equal to 65 years of age).
- Trial name
- NCT00406848
- Testing
- duloxetine hydrochloride
- Where
- 33 sites in United States, France and 2 more
- Volunteers
- 370 people
- Sponsor
- Eli Lilly and Company
Depression - Major Depressive Disorder, Transcranial Alternating Current Stimulation
Closed-Loop Transcranial Alternating Current Stimulation for the Treatment of Major Depressive Disorder
The purpose of this research study is to investigate a closed-loop transcranial alternating current stimulation (tACS) device to evaluate its ability to reduce symptoms of major depressive disorder
- Trial name
- NCT07282678
- Testing
- Closed-loop tACS
- Where
- United States
- Volunteers
- 214 people
- Sponsor
- Pulvinar Neuro, LLC
Major Depressive Disorder
A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients With Major Depressive Disorder
The purpose of this study is to evaluate the safety and efficacy in patients with major depressive disorder.
- Trial name
- NCT02395978
- Testing
- PDC-1421 Capsule
- Where
- 5 sites in United States, Taiwan
- Volunteers
- 72 people
- Sponsor
- BioLite, Inc.
Breast Cancer
Online Stress Management and Coping Skills Training for Women With Breast Cancer
Stress Management interventions have been shown to decrease cancer-related distress, foster emotional growth and improve immune functioning during treatment for breast cancer.
- Trial name
- NCT01335152
- Testing
- Coping with Breast Cancer web-based workbook
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Talaria, Inc
Major Depressive Disorder
Efficacy of Vortioxetine Versus Escitalopram on Cognitive Function in Patients With Inadequate Response to Current Antidepressant Treatment of Major Depressive Disorder
This study aims at evaluating the effect of vortioxetine on cognitive dysfunction in major depressive disorder (MDD) patients with inadequate response to current antidepressant treatment.
- Trial name
- NCT02272517
- Testing
- Vortioxetine 10-20 mg, Escitalopram 10-20 mg
- Where
- 16 sites in Finland, Germany and 2 more
- Volunteers
- 101 people
- Sponsor
- H. Lundbeck A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.